Vernet-les-Bains , guide touristique 1958, le Canigou... [Signé : G. Combrade et J.-B. Raynier.]

Contient une table des matièresAvec mode text

Supplementary Figures S1-S8 from Mass Cytometry Reveals Classical Monocytes, NK Cells, and ICOS⁺ CD4⁺ T Cells Associated with Pembrolizumab Efficacy in Patients with Lung Cancer

Supplementary Figure 1: Graphical Abstract Supplementary Figure 2: Overall Survival in NSCLC patients treated with pembrolizumab in KEYNOTE-001 according to EGFR mutation Supplementary Figure 3: Recursive partitioning identified classical monocytes and NK as the main immune populations whose frequency splits patients into distinct patterns of overall survival Supplementary Figure 4: Classical monocytes, NK cells and ICOS+ CD4+ T cells are associated with improved pembrolizumab efficacy in advanced NSCLC patients. Supplementary Figure 5: Gating strategy of the 3 main immune populations associated with pembrolizumab efficacy. Supplementary Figure 6: Comparison side by side of Maxstat cut-offs with cut-off from Younden index for overall survival in the 3 populations of interest. Supplementary Figure 7: Survival outcomes in NSCLC patients treated with pembrolizumab in KEYNOTE-001 according to blood baseline frequency of classical monocytes. Supplementary Figure 8: Baseline immune peripheral score is also associated with PFS in melanoma patients treated with PD-1 inhibitors.</p

Supplementary Tables S1-S4 from Mass Cytometry Reveals Classical Monocytes, NK Cells, and ICOS⁺ CD4⁺ T Cells Associated with Pembrolizumab Efficacy in Patients with Lung Cancer

Supplementary Table 1: List of antibodies used in the mass cytometry panel Supplementary Table 2: Number of immune cells analysed by CYTOF in our cohort Supplementary Table 3: Demographic and clinical characteristics of the CyTOF UCLA cohort (n=27), the Total UCLA cohort (n=97) and the Total KEYNOTE-001 (n=495) of non-small cell lung cancer patients Supplementary Table 4: Cox's proportional hazards model for overall survival in NSCLC patients treated with pembrolizumab in KEYNOTE-001</p